Table 1.
Distribution of various characteristics of treatment and survival in 176 glioblastoma from Sweden and Denmark
| Sweden (n = 108) | Denmark (n = 68) | Total (n = 176) | ||||
|---|---|---|---|---|---|---|
| Total | Missing | Total | Missing | Total | Missing | |
| Survival (months) | ||||||
| Mean | 16.1 | 15.1 | 15.7 | |||
| Median | 12.4 | 14.2 | 12.8 | |||
| Range | 2.1–71.8 | 1.0–51.9 | 1.0–71.8 | |||
| Gross total resection, n (%) | 6 (5.6%) | 1 (1.5%) | 169 (96.0%) | 7 (4.0%) | ||
| Yes | 26 (24.1%) | 24 (35.3%) | 50 (29.6%) | |||
| No | 76 (70.4%) | 43 (63.2%) | 119 (70.4%) | |||
| Chemotherapy, n (%) | 13 (12.0%) | 10 (14.7%) | 153 (86.9%) | 23 (13.1%) | ||
| Yes | 69 (63.9%) | 14 (20.6%) | 83 (54.2%) | |||
| Temozolomide | 29 (42.0%) | 11 (78.6%) | 40 (48.2%) | |||
| No | 26 (24.1%) | 44 (64.7%) | 70 (45.8%) | |||
| Radiotherapy, n (%) | 7 (6.5%) | 2 (2.9%) | 167 (94.9%) | 9 (5.1%) | ||
| Yes | 90 (83.3%) | 57 (83.8%) | 147 (88.0%) | |||
| Total dose 59–60 Gy | 13 (14.4%) | 40 (70.2%) | 53 (36.1%) | |||
| Total dose 50–58 Gy | 54 (60.0%) | 2 (12.3%) | 56 (38.1%) | |||
| Total dose <50 Gy | 16 (17.8%) | 7 (12.3%) | 23 (15.6%) | |||
| Total dose unknown | 7 (7.8%) | 8 (14.0%) | 15 (10.2%) | |||
| No | 11 (10.2%) | 9 (13.2%) | 20 (12.0%) | |||
| Number of deaths, n (%) | 92 (85.2%) | 10 (9.3%) | 66 (97.1%) | 158 (89.8%) | 10 (5.7%) | |
| Sex, n (%) | 176 (100%) | |||||
| Male | 66 (61.1%) | 43 (63.2%) | 109 (61.9%) | |||
| Female | 42 (38.9%) | 25 (36.8%) | 67 (38.1%) | |||
| Age median (years) | 56 | 56 | 56 | |||